Promentis Begins Study for SXC-2023 Targeting Neuropsychiatric Disorders

Promentis announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023. Promentis is developing SXC-2023 and other compounds that engage System xc-, a central nervous system (CNS) target addressing glutamatergic imbalance and oxidative stress, to treat obsessive-compulsive and related disorders, substance-related and addictive disorders and other neuropsychiatric disorders. SXC-2023 has demonstrated a compelling profile across a range of non-clinical studies.

Promentis' first indication is trichotillomania, a disabling and underrecognized condition characterized by recurrent hair pulling leading to noticeable hair loss and substantial adverse impact on quality of life, health and employment. Trichotillomania has been estimated to affect approximately 1% of the US population, and no medications are approved by the US Food and Drug Administration for the treatment of this chronic disorder.

"Promentis has met a number of key milestones in the past year. The company is particularly pleased to have commenced its clinical program and remains well-positioned to start its Phase 2 clinical work late next year," Daniel Lawton, President of Promentis, said. "Promentis is dedicated to making a difference in the lives of patients with trichotillomania and other neuropsychiatric disorders."